Ttk peptides and vaccines including the same

An amino acid, the following group technology, applied in the field of drugs for the treatment and prevention of tumors, can solve problems such as low objective response rate

Inactive Publication Date: 2012-05-16
ONCOTHERAPY SCI INC
View PDF29 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, many current cancer vaccine trials show only low objective response rates (NPL 11/Belli F et al., J Clin Oncol 2002 Oct 15

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ttk peptides and vaccines including the same
  • Ttk peptides and vaccines including the same
  • Ttk peptides and vaccines including the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0338] Materials and Method

[0339] Cell line

[0340] T2 (HLA-A2), human B lymphoblastoid cell line and COS7, African green monkey kidney cell line were purchased from ATCC. HLA-A2-positive and TTK-positive tumor cell line H1650 was purchased from ATCC. The HLA-A2 negative and TTK positive cell lines PC-3 and TE-1 were purchased from JCRB cell bank and RIKEN cell bank, respectively.

[0341] Synthesis of peptides derived from TTK

[0342] Based on the prediction of binding affinity for HLA-A*0201 molecules, 9-mer and 10-mer peptides derived from TTK (SEQ ID NO: 1 to 38) were designed. These peptides were synthesized by SIGMA (Sapporo, Japan) or Biosynthesis Inc. (Lewisville, TX) according to standard solid phase synthesis methods, and purified by reversed-phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptide were determined by analytical HPLC and mass spectrometry analysis, respectively. The peptide was dissolved in dimethyl sulfox...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Description

Technical field [0001] priority [0002] This application claims the rights and interests of U.S. Provisional Application No. 61 / 216,017 filed on May 11, 2009, and incorporates all of its contents into this article through the description. [0003] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. In particular, the present invention relates to novel peptides that are extremely effective as cancer vaccines and drugs for treating and preventing tumors. Background technique [0004] It has been proved that CD8-positive CTL can recognize epitope peptides derived from tumor-associated antigen (TAA) found on major histocompatibility complex (MHC) class I molecules, and then kill tumor cells. Since the first example of TAA-the melanoma antigen (MAGE) family was discovered, many other TAAs have been discovered mainly through immunological means (NPL 1 / Boon T, Int J Cancer 1993 May 8, 54(2 ): 177-80; NPL 2 / Boon T & van d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K7/06A61K38/00A61P35/00C07K16/18C12N15/09
CPCA61K38/00C07K14/4748A61K39/0011A61K2039/572A61P35/00A61P37/04A61P43/00C07K7/06C07K16/18C12N15/11
Inventor 中村佑辅角田卓也大泽龙司吉村祥子渡边朝久
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap